Zacks Investment Research·6 days ago
Amgen or Biogen: Which Biotech Stock Appears Better Poised?AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.
Biogen Inc.(BIIB)Earnings, Financials & Key Ratios
BIIB•NASDAQ
$205.70
23.3× P/E·Price updated Jul 7, 2026
AboutBiogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$9.81B+1.4%
- EBITDA$2.81B-11.1%
- Net Income$1.29B-20.8%
- EPS (Diluted)8.83-21.1%
- Gross Margin70.47%-7.4%
- EBITDA Margin28.67%-12.3%
- Operating Margin19.14%-25.6%
- Net Margin13.18%-21.8%
- ROE7.4%-28.6%
BIIB Price & Volume
Biogen Inc. (BIIB) stock price & volume — 10-year historical chart
Loading chart...
Biogen Navigates Volatile Neurology Franchise Transition Period
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Fortress
Cash Flow:Mixed
Primary Risk:Neurology pipeline execution failure
Key Thesis Takeaways
- Biogen is currently navigating a complex strategic transition as it attempts to offset the secular decline of its legacy multiple sclerosis franchise with new product launches.
- While the company maintains a fortress balance sheet with $3.4 billion in cash as of 2026Q1, investors should monitor the persistent volatility in operating margins, which swung from a negative 2.5% in 2025Q4 to 16.0% in 2026Q1.
- The long-term outlook remains contingent on the company's ability to stabilize its neurology pipeline and improve the commercial returns on its $6.5 billion goodwill base.
Verdict Logic
while the company maintains a robust liquidity position with a current ratio of 3.06 as of 2026Q1, the extreme volatility in earnings quality and inconsistent revenue growth suggest that the stock's 24.47 P/E ratio may not yet fully account for the risks inherent in its pipeline execution.
BIIB Growth Metrics
Biogen Inc. (BIIB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-0.92%
5 Years-6.11%
3 Years-1.2%
TTM0.42%
Profit CAGR
10 Years-9.6%
5 Years-20.22%
3 Years-24.85%
TTM-7.23%
EPS CAGR
10 Years-5.37%
5 Years-18.66%
3 Years-24.93%
TTM-7.8%
Return on Capital
10 Years19.2%
5 Years11.18%
3 Years9.32%
Last Year7.72%
BIIB Recent Earnings
Biogen Inc. (BIIB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$3.57+17.0%
$3.05
Rev
$2.5B+8.4%
$2.3B
Q1 2026
Feb 6, 2026Metric
Actual
Est
EPS
$1.99+22.1%
$1.63
Rev
$2.3B+3.5%
$2.2B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$4.81+24.0%
$3.88
Rev
$2.5B+4.9%
$2.3B
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$5.47+40.3%
$3.90
Rev
$2.6B+13.6%
$2.3B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $3.57vs $3.05+17.0% | $2.5Bvs $2.3B+8.4% |
| Q1 2026 | Feb 6, 2026 | $1.99vs $1.63+22.1% | $2.3Bvs $2.2B+3.5% |
| Q4 2025 | Oct 30, 2025 | $4.81vs $3.88+24.0% | $2.5Bvs $2.3B+4.9% |
| Q3 2025 | Jul 31, 2025 | $5.47vs $3.90+40.3% | $2.6Bvs $2.3B+13.6% |
Based on last 12 quarters of dataView full earnings history →
Latest BIIB News
Recent stock market news and headlines for Biogen Inc. (BIIB)
Zacks Investment Research·Jun 30, 2026
New Strong Sell Stocks for June 30thBBIB, BGSI and CLCGY have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2026.
Zacks Investment Research·Jun 29, 2026
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week HighsLLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
Zacks Investment Research·Jun 29, 2026
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
GlobeNewsWire·Jun 29, 2026
Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for DiranersenCAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer's disease portfolio at the Alzheimer's Association International Conference (AAIC) 2026, taking place July 12-15 in London, UK. Presentations will include data from the Phase 2 CELIA study evaluating diranersen, an investigational tau-targeting antisense oligonucleotide (ASO), and new analyses from studies of LEQEMBI® (lecanemab).
Peers Comparison
Key metrics vs top competitors for Biogen Inc. (BIIB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $205.70 | $30.37B | 23.30 | 1.39% | 13.18% | 7.4% | — | |
| $676.23 | $70.26B | 16.30 | 0.99% | 29.65% | 14.32% | — | |
| $522.25 | $132.84B | 34.09 | 9.57% | 35.4% | 23.93% | — | |
| $60.35 | $11.61B | 33.53 | 12.87% | 8.29% | 4.41% | — | |
| $321.59 | $42.91B | 138.02 | 65.19% | 13.46% | 98.29% | — | |
| $136.36 | $169.3B | 20.11 | 2.39% | 30.99% | 42.33% | — |
Compare BIIB vs Peers
Biogen Inc. (BIIB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BIIB SEC Filings & Documents
Biogen Inc. (BIIB) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Apr 6, 2026·SEC
Material company update
Mar 31, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when BIIB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BIIB Frequently Asked Questions
Biogen Inc. (BIIB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Biogen Inc.'s revenue?
Biogen Inc. (BIIB) reported $9.86B in revenue for fiscal year 2025. This represents a 3457% increase from $277.1M in 1996.
How fast is Biogen Inc. growing?
Biogen Inc. (BIIB) grew revenue by 1.4% over the past year. Growth has been modest.
Is BIIB profitable?
Yes, Biogen Inc. (BIIB) is profitable, generating $1.37B in net income for fiscal year 2025 (13.2% net margin).
Dividend & Returns
What is BIIB's return on equity?
Biogen Inc. (BIIB) has a return on equity (ROE) of 7.4%. This is below average, suggesting room for improvement.
What is Biogen Inc.'s free cash flow?
Biogen Inc. (BIIB) generated $2.62B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.